Evidence map›Paper›PMID 37310509›Full record

SynthesisArchives of virology2023

The antiviral potential of Phyllanthus species: a systematic review.

Richa Upadhyay, Kavindra Nath Tiwari

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Archives of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. A review ofFrontiers in pharmacology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Richa UpadhyayDepartment of Botany, Mihir Bhoj PG College, Dadri, G.B. Nagar, 203207, Uttar Pradesh, India.
Kavindra Nath TiwariDepartment of Botany, MMV, Banaras Hindu University, Varanasi, 221005, Uttar Pradesh, India. kntiwaribhu@gmail.com.ORCID http://orcid.org/0000-0002-8951-9057
Banaras Hindu University · IN

Funding

IOE scheme, BHU 6031
6 · The paper itself

Abstract

Viral infections and diseases caused by viruses are worldwide problems. According to a WHO report, three to five million people are chronically infected with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) each year globally. Since some viruses mutate very quickly, developing antiviral drugs can be a daunting task. Moreover, currently used synthetic drugs are toxic and associated with side effects. Therefore, there is a need to search for alternative natural remedies that have low toxicity, a new mechanism of action, and no major side effects. Phyllanthus plants have traditionally been used to treat viral hepatitis and liver damage in many tropical and subtropical countries worldwide. In this review, we discuss the therapeutic potential of Phyllanthus spp. against HBV, HCV, HIV, herpes simplex virus, and SARS-CoV-2. The inferences from in vitro and in vivo studies and clinical trials validate the use of Phyllanthus in antiviral remedies.

Indexed as

COVID-19Hepatitis CHIV InfectionsPhyllanthusAntiviral AgentsHepacivirusHepatitis B virusHumansSARS-CoV-2Antiviral Agents

Identifiers

PMID37310509
OpenAlexW4380423161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.